Table. 1 Clinical characteristics of the total study population (N = 44) at baseline including the comparison between adjuvant- and neoadjuvant-treated patients.
Baseline characteristics | Total n = 44 | Adjuvant n = 26 | Neoadjuvant n = 18 | p value |
|---|---|---|---|---|
Age – Years | ||||
Mean (SD) | 59 (6) | 59 (6) | 58 (5) | 0.478 |
BMI - kg/m2 | ||||
Median (IQR) | 26 (5) | 26 (4) | 26 (7) | 0.943 |
Weight loss past 3–6 months - in kg | ||||
<5% | 40 (91) | 24 (92) | 16 (89) | 1.000 |
5–10% | 4 (9) | 2 (8) | 2 (11) | |
Clinical tumour stage - No (%)1 | ||||
Stage I | 17 (40) | 15 (58) | 2 (12) | 0.001 |
Stage II | 23 (54) | 11 (42) | 12 (71) | |
Stage III | 3 (7) | 0 (0) | 3 (18) | |
Tumour-type - No (%) | ||||
Invasive carcinoma of no special type (NST) | 33 (75) | 17 (65) | 16 (89) | 0.089 |
Lobular | 8 (18) | 6 (23) | 2 (11) | |
Mucinous | 2 (5) | 2 (8) | 0 (0) | |
Unknown | 1 (2) | 1 (4) | 0 (0) | |
Therapeutic antibiotic use last year - No. (%) | 12 (27) | 8 (31) | 4 (22) | 0.733 |
Weeks between collection T0 faecal sample and last therapeutic antibiotic treatment | ||||
Mean (SD) | 31 (13) | 29 (12) | 33 (15) | 0.713 |
Karnofsky Performance Score - No (%)* | ||||
70–80 | 9 (21) | 7 (27) | 2 (11) | 0.006 |
90–100 | 35 (79) | 19 (73) | 16 (89) | |
MUST-score - No (%) | ||||
Low risk | 38 (86) | 22 (85) | 16 (89) | 0.688 |
Medium risk | 6 (14) | 4 (15) | 2 (11) | |
High risk | 0 (0) | 0 (0) | 0 (0) | |
Oral contraception use past | 34 (77) | 19 (73) | 15 (83) | 0.489 |
